Evaluation and comparison of a new DOTA and DTPA - bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor models
| Autor: | Julie Foster, Elaine Bortoleti de Araújo, Priscilla B. Pujatti, Kerly F.M. Pasqualoto, Jane K. Sosabowski, Stephen J. Mather, Jerome Burnet, Ciara Finucane, Jair Mengatti, Chantelle D. Hudson |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Agonist medicine.medical_specialty medicine.drug_class media_common.quotation_subject Breast Neoplasms Mice SCID In Vitro Techniques Heterocyclic Compounds 1-Ring chemistry.chemical_compound Drug Stability In vivo Cell Line Tumor Internal medicine LNCaP medicine Animals Humans DOTA Tissue Distribution Radionuclide Imaging Internalization neoplasms media_common Radiation Chemistry Indium Radioisotopes In vitro toxicology Prostatic Neoplasms Bombesin Pentetic Acid In vitro Receptors Bombesin Endocrinology Cancer research Heterografts Female Radiopharmaceuticals Neoplasm Transplantation |
| Zdroj: | Applied Radiation and Isotopes. 96:91-101 |
| ISSN: | 0969-8043 |
| DOI: | 10.1016/j.apradiso.2014.11.006 |
| Popis: | We evaluated and compared a new bombesin analog [Tyr–Gly 5 , Nle 14 ]-BBN(6–14) conjugated to DOTA or DTPA and radiolabeled with In-111 in low and high GRPR expressing tumor models. Both peptides were radiolabeled with high radiochemical purity and specific activity. In vitro assays on T-47D, LNCaP and PC-3 cells showed that the affinity of peptides is similar and a higher binding and internalization of DOTA-peptide to PC-3 cells was observed. Both peptides could target PC-3 and LNCaP tumors in vivo and both tumor types could be visualized by microSPECT/CT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect